Mainz Biomed shares surge 44.13% intraday after showcasing innovative cancer detection solutions at MEDICA 2025.

Mainz Biomed surged 44.13% during intraday trading following its announcement to showcase innovative cancer detection solutions at MEDICA 2025. This event highlights the company’s advancements in colorectal and pancreatic cancer screening technologies, including the commercial launch of ColoAlert® in Switzerland and regulatory progress in the UK. Recent developments, such as top-line results from feasibility studies and partnerships with organizations like EDX Medical Group, have reinforced investor confidence in its pipeline. The timing of the MEDICA 2025 announcement aligns with the stock’s sharp intraday rally, signaling renewed market optimism about the company’s diagnostic solutions and growth prospects in oncology.